|View printer-friendly version|
|November 30, 1999 10:37 a.m.|
|Teva Pharmaceutical Receives First FDA Approval Of Buproprion Tablets|
|Jerusalem, Israel, November 30, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it had received from the US Food and Drug Administration an approval to manufacture and market Buproprion Tablets (in two strengths, 75mg and 100mg). Teva USA will launch the product in the USA imminently. |
Buproprion is Teva's generic version of Glaxo Wellcome's anti-depressant drug Wellbutring, of which annual US sales are approximately $110 million.
Teva views this approval as significant as it is the first approval for a generic version of this drug.
Teva Pharmaceutical Industries Ltd. is Israel's largest pharmaceutical company, with 80% of its sales outside Israel, mainly in the United States. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, active pharmaceutical ingredients, medical disposables and veterinary products.
Safe Harbor Statement: This release contains-forward looking statements which express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, fluctuations in currency, exchange and interest rates, operating results, the impact of the year 2000 issue and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission.
|Teva Pharmaceutical Industries Ltd |